UAE- Julphar makes H1 net profit of Dh133.8 million
Date
8/16/2016 12:34:19 AM
Gulf
Pharmaceutical Industries, or Julphar, has announced sales revenue of Dh759.7 million in the first half of this year. The company posted a gross
profit of Dh465.7 million and its net profit for the period was Dh133.8 million.
Dr Ayman Sahli, CEO of Julphar, said: "We have accomplished significant progress. We have launched the real-time continuous glucose monitoring device and Dexcom G4 Platinum in Jordan. As part of our commitment to contribute to better healthcare in the region, we have launched new products in our targeted markets: the general inhalational anesthetic Sojourn in Saudi Arabia, Mebo Scar in Algeria and the new Proton Pump Inhibitor Pantonix tablets in the UAE."
"In June, Julphar Bangladesh received the ISO certification from the Bangladesh Accreditation Board. We are planning to begin Julphar Saudi Arabia operations in the coming months," he added. - Wam
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.